Sutro Bio in progress trending company
Trending Company

(6/28/22)

EU Biopharma Co. Makes $247M Bid for US Oncology Co.
Source: Streetwise Reports (06/27/2022)

Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.

The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.

Gene Therapy Co. Releases Data From Huntington's Study
Source: Streetwise Reports (06/23/2022)

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Source: Streetwise Reports (06/22/2022)

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.